Evidence map›Paper›PMID 42312207›Full record

Trial reportFrontiers in endocrinology2026

Baseline serum metabolites predict fractures in individuals who were Black and had type 2 diabetes.

Carolyn Chlebek, Valerie Bussberg, Niven R Narain, Michael A Kiebish, Yu-Hua Tseng, Clifford J Rosen, Matthew D Lynes

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000620. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000620 phase3completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Ran1999Enrolled10,251Registered outcomes6Posted comparisons6ConditionsAtherosclerosis, Cardiovascular Diseases, Coronary Disease, Diabetes MellitusArmsAnti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carolyn ChlebekCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, United States.
Valerie BussbergBPGBio, Framingham, MA, United States.
Niven R NarainBPGBio, Framingham, MA, United States.
Michael A KiebishBPGBio, Framingham, MA, United States.
Yu-Hua TsengJoslin Diabetes Center, Harvard Medical School, Boston, MA, United States.
Clifford J RosenCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, United States.
Matthew D LynesCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, United States.

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
TRAINING IN DIABETES AND METABOLISMT32DK007260 · NIDDK · JOSLIN DIABETES CENTER · PI LAURIE J GOODYEAR · 1986 to 2026
$13.6M
Fibroblast Growth Factor and Energy MetabolismR01DK102898 · NIDDK · JOSLIN DIABETES CENTER · PI TSENG, YU-HUA · 2015 to 2024
$4.1M
Role of brown fat-derived specialized pro-resolving lipid mediators in inflammation and metabolismR01DK122808 · NIDDK · JOSLIN DIABETES CENTER · PI SPITE, MATTHEW R, TSENG, YU-HUA · 2020 to 2023
$2.2M
The Lipidomics of Adipose Tissue ThermogenesisK01DK111714 · NIDDK · MAINEHEALTH · PI LYNES, MATTHEW D · 2017 to 2021
$804k
Telomerase as a Marker of Brown and White Adipose Tissue Stem CellsF32DK102320 · NIDDK · JOSLIN DIABETES CENTER · PI LYNES, MATTHEW D · 2014 to 2014
$53k
NIDDK NIH HHS F32 DK102320NIDDK NIH HHS K01 DK111714NIDDK NIH HHS P30 DK036836NIDDK NIH HHS R01 DK102898NIDDK NIH HHS R01 DK122808NIDDK NIH HHS T32 DK007260
6 · The paper itself

Abstract

Background: Type 2 Diabetes Mellitus (T2D) is a metabolic disorder with increasing prevalence worldwide. Fractures are increased in people with T2D. Black patients have higher bone mineral density than White patients, suggesting the potential for distinct mechanisms for fracture within specific populations. Methods: To test whether changes to metabolism during T2D may contribute to skeletal fragility, we analyzed 465 targeted metabolites in serum collected at baseline from 571 participants (average age 62.1 years) in the Action to Control Cardiovascular Risk in Diabetes trial (ACCORD, ClinicalTrials.gov NCT00000620), a randomized clinical trial of patients with T2D. Participants with T2D were enrolled and serum was collected at baseline. These serum samples were obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center. We focused exclusively on ACCORD participants who were Black, an understudied population with regards to fracture risk. Following enrollment, participants were randomized to intensive or standard glycemia strategies, which did not affect fracture or fall risk. Using the longitudinal data from ACCORD BONE, we compared the baseline serum metabolome of participants who later fractured with those who did not fracture. Results: Individual metabolite analysis revealed circulating metabolites that were significantly different at baseline in those that fractured versus those who did not. One metabolite had both adjusted and unadjusted p-values that reached significance: 7,8-dihydrofolate, which is involved in folate-dependent one-carbon metabolism, was greater in participants who later fractured compared to those who did not fracture. Importantly, several metabolites related to the tricarboxylic acid cycle were reduced in participants who later fractured, with significant unadjusted p-values. Conclusion: In summary, the metabolic differences identified here highlight the role of altered systemic metabolism and its relationship to fracture risk. Future investigations will determine if the identified metabolites serve as predictors of fracture in patients with T2D who are not Black.

Indexed as

BiomarkersBlack or African AmericanDiabetes Mellitus, Type 2Fractures, BoneAgedBone DensityFemaleHumansMaleMetabolomicsMiddle AgedRisk FactorsBiomarkersbiomarkersethnic studiesfracture riskmetabolomicstype 2 diabetes mellitus

Identifiers

PMID42312207
PMCPMC13268917

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.